## 2024 Rachel Pearline Award Nomination Form

OMB # 0925-0766 Expiration Date: 09/30/2026

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form to this address.

The Rachel Pearline Award honors Rachel Pearline, MD, MPH. Dr. Pearline was a revered oncology fellow who received the award named in her memory in 2016 following her death at the age of 38, in November 2015, from gastric cancer. While in medical school, she completed rotations in South Africa, Haiti, Romania, and rural China where she learned to speak Mandarin fluently. For her work, she received a prestigious Fogarty International Clinical Research Fellowship and Tulane University's award for "Outstanding International Relationships." Dr. Pearline was virtuously committed to global cancer control and provided quality care to her patients. She viewed the practice of medicine as a privilege, always striving to serve her patients better.

In honor of Dr. Rachel Pearline, the 12th Annual Symposium on Global Cancer Research Steering Committee would like to invite nominations for the 2024 Annual Rachel Pearline Award. As part of the Symposium each year, we recognize one outstanding professional who embodies virtue and eminence in cancer research, practice, and/or training in a low- and middle-income country (LMIC) setting. The theme of the 2024 Symposium is "Collaborating for Impact" and the Steering Committee invites nominations of individuals, at any stage in their career, who have made major contributions to global cancer research, practice, and training. The nominee should be affiliated with an institution from a LMIC and their work should focus on cancer research, practice, and/or training in an LMIC setting.

The nominee will be recognized at the virtual Annual Symposium on Global Cancer Research, which will take place on May 6th - 9th, 2024, during a dedicated session on May 9th. The nominee will be expected to take part in the award presentation ceremony as well as to give a keynote address that highlights their contributions to cancer research, practice, and/or training in an LMIC setting, and their future perspectives.

\* Required

# The Steering Committee will review nominations based on the following criteria:

- 1. Demonstration of commitment to and excellence in cancer research, practice, and/or training
- 2. Focus on reducing inequities through cancer research, practice, and/or training
- 3. Affiliation with an institution based in an LMIC
- 4. Cancer control research, practice, and training activities either entirely or predominantly implemented in LMICs
- 5. Career stage and potential to contribute to cancer control in LMICs in the future

### Additional eligibility criteria:

- Nominations submitted in previous years are accepted
- Self-nominations are accepted
- Nominee must confirm willingness/ability to accept the award and deliver a keynote address, virtually, at the Symposium in advance of nomination submission (confirmation to be stated within the nomination form).

#### Timeline

The nomination period is January 8, 2024 through February 9, 2024.

The nominee will be selected and notified on March 4, 2024

## **Submitter Information**

1.	Submitter Email *
2.	Submitter Name *
3.	Submitter Institution *

## Nominee Information

4.	Nominee Name *			
_	Manuface Institution *			
ο.	Nominee Institution *			
ŝ.	Nominee Country *			
	•			
7.	Nominee Email *			
3.	In what capacity have you worked with the nominee, and for how long?  If self-nomination, please indicate that below. *			
9.	Please confirm the following: *			
	Yes, I have received the nominee's permission to nominate them for this award.			
	Yes, the nominee is able to attend virtually and give a keynote address at the 12th Annual Global Cancer Research Symposium, May 9th, 2024			

10.		ct the nominee's the region(s) of focus in their cancer research, practice, and/or training: additional context, please refer to: <a href="https://data.worldbank.org/country">https://data.worldbank.org/country</a>
		East Asia & Pacific
		Europe and Central Asia
		Middle East & North Africa
		South Asia
		Sub-Saharan Africa
		Latin American & Caribbean
		Other
11.		se list the nominee's specific country/countries of focus in their cancer research, practice, /or training:
		additional context, please refer to: <u>https://data.worldbank.org/country</u>
	For	additional context, please refer to: <u>https://data.worldbank.org/country</u>
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or hing:
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or hing: additional context, please refer to: https://www.icrpartnership.org/cso *
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or ning: additional context, please refer to: <a href="https://www.icrpartnership.org/cso">https://www.icrpartnership.org/cso</a> * Biology (how cancer starts and progresses)
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or ning: additional context, please refer to: <a href="https://www.icrpartnership.org/cso">https://www.icrpartnership.org/cso</a> *  Biology (how cancer starts and progresses)  Etiology (the causes or origins of cancer)
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or ning: additional context, please refer to: <a href="https://www.icrpartnership.org/cso">https://www.icrpartnership.org/cso</a> *  Biology (how cancer starts and progresses)  Etiology (the causes or origins of cancer)  Prevention
12.	For *  *  Sele train	ct the nominee's scientific area(s) of focus within cancer research, practice, and/or ning: additional context, please refer to: <a href="https://www.icrpartnership.org/cso">https://www.icrpartnership.org/cso</a> *  Biology (how cancer starts and progresses)  Etiology (the causes or origins of cancer)  Prevention  Early Detection, Diagnosis, and Prognosis

#### References

Please supply ONE reference that describes the nature of the nominee's work in cancer research, practice, and/or training in an LMIC setting.

The reference may be provided as a link to an external source below, OR if you would like to send an attachment please submit it to <a href="mailto:douglas.puricelliperin@nih.gov">douglas.puricelliperin@nih.gov</a>.

Accepted references include, but are not limited to: CV, professional bio, previous or current publications. Only one reference is necessary.

13.	Please provide URL reference link here: Accepted references include, but are not limited to: LinkedIn profile, professional website, professional bio, previous or current publications. Only one reference is necessary.
14.	In 300 words or less, please describe: - Why you are nominating this individual for the 2024 Rachel Pearline Award - Why you believe the nominee has achieved excellence in cancer research, practice, and/or training in a LMIC setting - Why you believe the nominee can give a compelling keynote address at the 2024 Symposium *

This content is neither created nor endorsed by Microsoft. The data you submit will be sent to the form owner.

Microsoft Forms